Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference45 articles.
1. Roskoski R (2016) Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res 113(Pt A):395–408
2. Barf T, Covey T, Izumi R et al (2017) Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240–252
3. (2018) Imbruvica® (ibrutinib) [package insert]. Janssen Biotech, Inc., Horsham, PA
4. (2019) Calquence® (acalabrutinib) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE
5. (2019) Brukinsa® (zanubrutinib) [package insert]. BeiGene USA, Inc., San Mateo, CA
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献